[1]
|
C.-E. Deng, “Progress on Pharmacological and Clinical Application of Salvia Miltiorrhiza,” Lishizhen Medicine and Materia Medica Research, Vol. 14, No. 12, 2003, p. 776.
|
[2]
|
N. Ding, “Research Advancement and Clinical Application of Compound Danshen,” Chinese Traditional and Herbal Drugs, Vol. 33, No. 12, 2002, pp. 1147-1148. (in Chinese)
|
[3]
|
Z. X. Guo, W. Jia, W. Y. Gao, et al., “Clinical Investigation of Composite Danshen Pill for the Treatment of Angina Pectoris,” Chinese Journal of Natural Medicines, Vol. 1, No. 2, 2003, pp. 124-128. (in Chinese)
|
[4]
|
Y. H. Shi, “Comparative Study of Composite Danshen Droplet Pills and Sordid in Treatment of Patients with Chronic Stable Angina,” Zhongguo Zhong Xi Yi Jie He Za Zhi, Vol. 17, No. 1, 1997, pp. 23-25. (in Chinese)
|
[5]
|
W. Zhou and T. J. Ruigrok, “Protective Effect of Danshen during Myocardial Ischemia and Reperfusion: An Isolated Rat Heart Study,” The American Journal of Chinese Medicine, Vol. 18, No. 1, 1990, pp. 19-24.
doi:10.1142/S0192415X90000046
|
[6]
|
A. M. Wang, S. H. Sha, W. Lesniak, et al., “Tanshinone (Salviae miltiorrhizae Extract) Preparations Attenuate Aminoglycoside-Induced Free Radical Formation: In Vitro and Ototoxicity in Vivo,” Antimicrobial Agents and Chemotherapy, Vol. 47, No. 6, 2003, pp. 1836-1841.
doi:10.1128/AAC.47.6.1836-1841.2003
|
[7]
|
J. Wang, J. Xu, J. B. Zhong, et al., “Effect of Radix Notoginseng Saponins on Platelet Activating Molecule Expression and Aggregation in Patients with Blood Hyperviscosity Syndrome,” Zhongguo Zhong Xi Yi Jie He Za Zhi, Vol. 24, No. 4, 2004, pp. 312-316. (in Chinese)
|
[8]
|
P. Chan, G. N. Thomas and B. Tomlinson, “Protective Effects of Trilinolein Extracted from Panax Notoginseng against Cardiovascular Disease,” Acta Pharmacologica Sinica, Vol. 23, No. 12, 2002, pp. 1157-1162.
|
[9]
|
W. Zhou, H. Chai, P. H. Lin, et al., “Molecular Mechanisms and Clinical Applications of Ginseng Root for Cardiovascular Disease,” Medical Science Monitor, Vol. 10, No. 8, 2004, pp. RA187-RA192.
|
[10]
|
Y.-J. Wu, C.-Y. Hong, S.-J. Lin, P. Wu and M.-S. Shiao, “Increase of Vitamin E Content in LDL and Reduction of Atherosclerosis in Cholesterol-Fed Rabbits by a WaterSoluble Antioxidant-Rich Fraction of Salvia miltiorrhiza,” Thrombosis, and Vascular Biology, Vol. 18, 1998, pp. 481-486. doi:10.1161/01.ATV.18.3.481
|
[11]
|
O. Karmin, E. G. Lynn, R. Vazhappilly, K. K. W. AuYeung, D.-Y. Zhu and Y. L. Siow, “Magnesium Tanshinoate B (MTB) Inhibits Low Density Lipoprotein Oxidation,” Life Sciences, Vol. 68, No. 8, 2001, pp. 903-912.
doi:10.1016/S0024-3205(00)00989-9
|
[12]
|
T. Kyoko, O. Xinshou, K. Katsuko, N. Norio, H. Masao and B. Akemichi, “Sodium Tanshinone IIA Sulfonate Derived from Danshen (Salvia miltiorrhiza) Attenuates Hypertrophy Induced by Angiotensin II in Cultured Neonatal Rat Cardiac Cells,” Biochemical Pharmacology, Vol. 64, No. 4, 2002, pp. 745-750.
doi:10.1016/S0006-2952(02)01250-9
|
[13]
|
G. Wang, L. Wang, Z. Y. Xiong, B. Mao and T. Q. Li, “Compound Salvia Pellet, a Traditional Chinese Medicine, for the Treatment of Chronic Stable Angina Pectoris Compared with Nitrates: A Meta-Analysis,” Medical Science Monitor, Vol. 12, No. 1, 2006, pp. SR1-SR7.
|
[14]
|
P. Mickie, R. Peled, L. Matityhau, et al., “Reasons for Overprescription of Mononitrates: The Paradigm of Stable Angina Pectoris Treatment,” Current Therapeutic Research, Vol. 64, No. 9, 2003, pp. 662-675.
doi:10.1016/j.curtheres.2003.09.013
|
[15]
|
S. P. Glasser, “Clinical Mechanisms of Nitrate Action,” American Journal of Cardiology, Vol. 81, No. 1, 1998, pp. 49A-53A. doi:10.1016/S0002-9149(97)00998-3
|
[16]
|
S. D. Fihn, S. V. Williams, J. Daley, et al., “American College of Cardiology, American Heart Association, American College of Physicians-American Society of Internal Medicine Guidelines for the Management of Patients with Chronic Stable Angina: Treatment,” Annals of Internal Medicine, Vol. 135, No. 8, 2001, pp. 616-632.
doi:10.7326/0003-4819-135-8_Part_1-200110160-00014
|
[17]
|
M. Eccles, “North of England Stable Angina Guideline Development Group: North of England Evidence Based Guidelines Development Project: Summary Version of Evidence Based Guideline for the Primary Care Management of Angina,” BMJ, Vol. 312, 1996, pp. 827-832.
doi:10.1136/bmj.312.7034.827
|
[18]
|
R. J. Gibbons, J. Abrams, K. Chatterjee, et al., “ACC/ AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina),” Circulation, Vol. 107, 2003, pp. 149-158. doi:10.1161/01.CIR.0000047041.66447.29
|
[19]
|
S. Silber, “Nitrates: Why and How Should They Be Used Today?” European Journal of Clinical Pharmacology, Vol. 3, No. 1, 1990, pp. S35-S51.
doi:10.1007/BF01417564
|
[20]
|
P. A. Todd, K. L. Goa and H. D. Langtry, “Transdermal Nitroglycerin (Glyceryl Trinitrate): A Review of Its Pharmacology and Therapeutic Use,” Drugs, Vol. 40, No. 6, 1990, pp. 880-902.
doi:10.2165/00003495-199040060-00009
|
[21]
|
S. Y. Zai, R. Chen and X. H. Wu, “Clinical Observation on Compound Salvia Pellet in the Treatment of 41 Cases’ Migraine,” Journal of Practical, Traditional Chinese Medicine, Vol. 22, No. 1, 2006, p. 26.
|
[22]
|
G. Y. Hu and F. H. Cai, “Clinical Observation of Curative Effect of Compound Danshen Pellet in Unstable Angina,” Chinese Journal of Cardiovascular Review, Vol. 1, No. 1, 2003, pp. 38-40.
|